US 11,725,198 B2
Treatment of gluten intolerance and related conditions
David C. Schriemer, Chestermere (CA); Petr Man, Prague (CZ); Hynek Mrazek, Prague (CZ); and Martial Rey, Calgary (CA)
Assigned to CODEXIS, INC., Redwood City, CA (US)
Filed by Codexis, Inc., Redwood City, CA (US)
Filed on Mar. 23, 2021, as Appl. No. 17/209,879.
Application 17/209,879 is a division of application No. 16/357,191, filed on Mar. 18, 2019, granted, now 10,982,201.
Application 14/620,066 is a division of application No. 13/843,369, filed on Mar. 15, 2013, granted, now 9,005,610, issued on Apr. 13, 2015.
Application 16/357,191 is a continuation of application No. 15/209,681, filed on Jul. 13, 2016, granted, now 10,266,818, issued on Apr. 22, 2019.
Application 15/209,681 is a continuation of application No. 14/620,066, filed on Feb. 11, 2015, abandoned.
Claims priority of provisional application 61/797,040, filed on Nov. 27, 2012.
Claims priority of provisional application 61/729,210, filed on Nov. 21, 2012.
Prior Publication US 2021/0230569 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 9/50 (2006.01); A61K 38/48 (2006.01); A23L 29/00 (2016.01); A23L 33/10 (2016.01); A23L 33/105 (2016.01); A61K 38/00 (2006.01)
CPC C12N 9/63 (2013.01) [A23L 29/06 (2016.08); A23L 33/10 (2016.08); A23L 33/105 (2016.08); A61K 38/488 (2013.01); C12Y 304/23012 (2013.01); A23V 2002/00 (2013.01); A61K 38/00 (2013.01)] 12 Claims
 
1. A method for treating or attenuating gluten intolerance in a patient in need thereof, comprising administering to said patient an effective amount of nepenthesin, wherein said nepenthesin comprises an amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, or SEQ ID NO: 7, wherein the nepenthesin has protease activity.